• US stock market daily report (August 04, 2015, Tuesday)

    According to American pharmaceutical company Aprecia, the US Food and Drug Administration (FDA) approved its drug Spritam, made by 3D printing for the first time.

    Aprecia's “ZipDose” technology works by printing together layers of powder with a fluid to make a “porous, water-soluble matrix that rapidly disintegrates with a sip of liquid.” The pharmaceutical company claims that even the strongest doses of the drug could be taken with just a sip of water.

    Aprecia wrote in its announcement that, “While 3DP [3D printing] has been used previously to manufacture medical devices, this approval marks the first time a drug product manufactured with this technology has been approved by the FDA.”

    Spritam is a branded version of the generic levetiracetam, an oral treatment to help treat seizures in patients with epilepsy.

    While Spritam has the same effect as the generic version, it is intended to improve the ease of taking it by literally making it easier to swallow.

    For years, Levetiracetam has been used as an anticonvulsant to treat epilepsy in the U.S.A. and the UK. Aprecia claims that its proprietary 3D-printed formulation disintegrates rapidly -in less than 10 seconds for a high-dose drug - and could offer more taste-masking possibilities.

    Contributed by Millennium Traders
About us
StockMarketsReview.com provides news coverage, analysis and researches for world stock markets, commodities and currencies. We publish articles provided by experts of leading brokerage and investment companies. At our website investors can find daily, weekly and monthly reports, news, recommendations on the IPOs and fundamental analysis for stocks which are currently traded at the stock exchange.